Osteoporosis & Osteopenia

Protecting Bone Health After MenopauseOsteoporosis (reduced bone strength with increased fracture risk) and osteopenia (lower-than-normal bone density, but not yet osteoporosis) are common in women after menopause. Bone loss accelerates in the first 5–10 years after menopause, largely due to declining oestrogen (the hormone that protects bone).What Happens to Bone After Menopause?Oestrogen plays a key role in maintaining the balance between bone breakdown and formation. After menopause:Bone resorption (breakdown) increasesBone formation cannot keep upNet bone loss occurs, increasing fracture riskWomen can lose up to 10–20% of bone density in the early postmenopausal years.The Role of OestrogenOestrogen is one of the most effective therapies for preventing bone loss.Evidence shows:Menopausal hormone therapy (MHT) reduces fracture risk by ~30–40%It improves bone mineral density (BMD) at the spine and...

The Menopause Client Agonists for weight loss

GLP-1 Agonists for Weight Loss, What You Need to Know

GLP-1 agonists such as Mounjaro and Wegovy® were originally developed to treat type 2 diabetes, but in recent years, they’ve gained widespread attention for a different reason: supporting significant weight loss. These medications work by mimicking a hormone called glucagon-like peptide-1 (GLP-1), which helps regulate: • Appetite • Insulin secretion • Glucose metabolism The result? You feel fuller for longer, have fewer cravings, and are more in control of your eating—especially helpful during midlife, when metabolism slows and managing weight becomes increasingly challenging. How GLP-1 Agonists Support Weight Loss GLP-1 medications like Wegovy and Mounjaro help: • Reduce appetite and hunger • Slow gastric emptying (helping you feel full) • Improve insulin sensitivity This mechanism makes them a valuable tool in midlife weight management, particularly during menopause, when hormonal changes often lead to weight gain around...